ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Horizon Acquires Arthritis Drug

by Rick Mullin
November 25, 2013 | APPEARED IN VOLUME 91, ISSUE 47

Horizon Pharma will pay $35 million to acquire AstraZeneca’s rights to Vimovo, a delayed-release drug approved to treat osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Vimovo (naproxen/esomeprazole magnesium) can also be used to decrease the risk of gastric ulcers. Under the terms of the agreement, Horizon Pharma will pay 10% royalties to Pozen, AstraZeneca’s partner in developing and marketing the drug.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment